First author/year | Location | Design | AKI criteria | Population | Sample size | Furosemide dose | Urine output cutoff point | Outcome of interest | Enrolled patients AKI stage | High plasma NGAL | Exclusion of chronic kidney disease |
---|---|---|---|---|---|---|---|---|---|---|---|
Chawla, 2013 [8] | USA | PC+RC | AKIN | Mixed | 77 | 1 mg/kg (furosemide naïve) or 1.5 mg/kg (furosemide non-naive) | 200 ml/2 h | AKIN stage 3 | AKIN stage 1–2 | Yes | Yes (eGFR < 30) |
Elsaegh, 2018 [14] | Egypt | PC | KDIGO | Sepsis | 60 | KDIGO stage progression (included RRT) | Normal renal function and any stage of AKI | No | Yes | ||
Lumlertgul, 2018 [15] | Thailand | PC | KDIGO | Mixed | 162 | RRT | Any stage of AKI | Yes | Yes (baseline Cr > 2) | ||
Martínez, 2016 [16] | Mexico | PC | KDGO | NA | 20 | KDIGO stage-3 and RRT | KDIGO stage 1–2 | No | Yes (eGFR < 30) | ||
Matsuura, 2018 [17] | Japan | RC | KDIGO | Mixed | 51 | NA | 3.9 ml/2 h for per milligram furosemide | KDIGO stage 3 and RRT | KDIGO stage 1–2 or high NGAL with normal renal function | Yes | No |
Pérez-Cruz, 2017 [18] | Mexico | PC | AKIN | Medical | 35 | 1 mg/kg (furosemide naive) or 1.5 mg/kg (furosemide non-naive) | 200 ml/2 h | AKIN-3 and RRT | AKIN stage 1–2 | No | No |
Rewa, 2019 [19] | USA and Canada | PC | AKIN | Mixed | 92 | AKIN stage 3 | AKIN stage 1–2 | No | Yes (eGFR < 30) | ||
Saber, 2018 [20] | Egypt | PC | AKIN | NA | 40 | 325 ml/6 h | AKIN stage 3 (included RRT) | AKIN stage 1–2 | No | Yes (eGFR < 30) | |
Sakhuja, 2019 [21] | USA | RC | AKIN | NA | 687 | ≥ 1 mg/kg | 600 ml/6 h | RRT | AKIN stage 3 | No | No |
Vairakkani, 2019 [22] | India | NA | KDIGO | NA | 80 | 1 mg/kg (furosemide naive) or 1.5 mg/kg (furosemide non-naive) | 325 ml/2 h | KDIGO stage 3 | KDIGO stage 1–2 | No | Yes (eGFR < 30) |
Venugopal, 2019 [23] | India | PC | AKIN | NA | 62 | 200 ml/2 h | AKIN-3 and RRT | AKIN stage 1–2 | No | No |